Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis

被引:222
|
作者
Gao, Wen [1 ]
Yu, Yue [2 ]
Cao, Hailong [3 ]
Shen, Hua [1 ]
Li, Xiaodong [1 ]
Pan, Shiyang [4 ]
Shu, Yongqian [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing 210029, Peoples R China
[2] Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Dept Liver Surg, Nanjing 210029, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Nanjing 210029, Peoples R China
[4] Nanjing Med Univ, Affiliated Hosp 1, Dept Clin Lab, Nanjing 210029, Peoples R China
关键词
MicroRNA; Microarray; qRT-PCR; Non small cell lung cancer; Prognosis; TUMOR-SUPPRESSOR GENE; MICRORNA GENES; REDUCED EXPRESSION; LET-7; RAS; PROFILES; MUTATION; CLUSTER; STAGE; ADENOCARCINOMA;
D O I
10.1016/j.biopha.2010.01.018
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Context - MicroRNAs (miRNAs) represent a class of small non-coding RNAs that regulate the gene expressions at the posttranscriptional level, subsequently control crucial physiological processes. Recent evidence demonstrates that some miRNAs have the functions similar to oncogene or tumor suppressors, It may play important roles in tumorigenesis MiRNA expression profiles may become useful biomarkers for cancer diagnostics, prognosis and prediction of response to treatment, and it could be a powerful tool for cancer prevention and therapeutics Objective - To explore the global expression profile of miRNAs in non small cell lung cancer (NSCLC) and its potential relevance to clinicopathological characteristics and prognosis. Methods. - LNA microRNA microarrays were utilized to detect miRNA expression levels in eight surgically removed lung carcinoma tissues (La) and their corresponding normal lung tissues (NT) After initial microarray validation by quantitative real-time reverse transcription polymerase chain reaction assays (qRT-PCR), miR-21, miR-143 and miR-181a were selected for further study in another 47 paired LCTs and matched NTs by qRT-PCR using Taqman microRNA assay. Results. - Twenty-seven microRNAs were observed to be deregulated greater than two-fold in LCT compared with NT by microarray. Consistenting with the microarray, the expression level of miR-21 by qRT-PCR was significantly higher in tumor tissues than in adjacent normal tissues (P = 0026); while miR-143 (P = 0.000) and miR-181a (P= 0.000) were downregulated in LCT. Interestingly, among the 47 NSCLC cases, low level expression of miR-143 was significantly correlated with smoking status (P= 0026), high miR-21 expression (hazard ratio, 5993, 95% confidence interval, 2 518-14.264; P= 0.000) and low miR-181a expression (hazard ratio, 0.328, 95% confidence interval 0.142-0 756; P = 0.009) were associated with poor survival, independent of clinical covariates. including TNM staging, lymph note status. Conclusion. - Our data thus indicating the potential of miR-21, miR-143 and miR-181a as a novel diagnostic or prognostic biomarker for NSCLC. Besides, these data will guide further studies of specific microRNAs might become potential targets for therapeutic intervention. (C) 2010 Elsevier Masson SAS All rights reserved.
引用
收藏
页码:399 / 408
页数:10
相关论文
共 50 条
  • [31] The miR-21:miR-221 ratio as a serum-based diagnostic for non-small cell lung cancer
    Karkera, Jayaprakash
    Gaffney, Dana S.
    Londhe, Puja
    Wu, Xiaoying
    Fan, Hongtao
    Raponi, Mitch
    CANCER RESEARCH, 2010, 70
  • [32] Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening
    Yang, Jin-shan
    Li, Bao-jian
    Lu, Hua-wei
    Chen, Yu
    Lu, Chuan
    Zhu, Rui-xia
    Liu, Si-hai
    Yi, Qing-ting
    Li, Jing
    Song, Chun-hui
    TUMOR BIOLOGY, 2015, 36 (04) : 3035 - 3042
  • [33] Higher Expressions of miR-21, miR-106a, miR-181b, and miR-203 are Associated with Poor Prognosis in Colorectal Cancer Patients
    Bovell, Liselle
    Katkoori, Venkat R.
    Shanmugam, Chandrakumar
    Lee, Choo H.
    Meleth, Sreelatha
    Bumpers, Harvey L.
    Grizzle, William E.
    Manne, Upender
    CANCER RESEARCH, 2010, 70
  • [34] Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer
    Shen, Hua
    Zhu, Fang
    Liu, Jinyuan
    Xu, Tongpeng
    Pei, Dong
    Wang, Rong
    Qian, Yingying
    Li, Qi
    Wang, Lin
    Shi, Zhumei
    Zheng, Jitai
    Chen, Qiudan
    Jiang, Binghua
    Shu, Yongqian
    PLOS ONE, 2014, 9 (07):
  • [35] MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1
    Shi, Qin
    Zhou, Zhan
    Ye, Naishu
    Chen, Qiaolin
    Zheng, Xiuxia
    Fang, Minshan
    CANCER BIOMARKERS, 2017, 20 (04) : 539 - 546
  • [36] Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer
    Xu, Liyun
    Huang, Yanyan
    Chen, Dongdong
    He, Jianying
    Zhu, Wangyu
    Zhang, Yongkui
    Liu, Xiaoguang
    CANCER GENETICS, 2014, 207 (05) : 214 - 220
  • [37] Delivery of miR-143 and miR-506 with novel nano carrier to arrest cell cycle in lung cancer
    Hossian, A. K. M. Nawshad
    Muthumula, Chandra Mohan Reddy
    Mattheolabakis, George
    CANCER RESEARCH, 2019, 79 (13)
  • [38] Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development
    Dimitrova, Nadya
    Gocheva, Vasilena
    Bhutkar, Arjun
    Resnick, Rebecca
    Jong, Robyn M.
    Miller, Kathryn M.
    Bendor, Jordan
    Jacks, Tyler
    CANCER DISCOVERY, 2016, 6 (02) : 188 - 201
  • [39] miR-21 Inhibits Non-Small Cell Lung Cancer Cell Proliferation and Promotes Apoptosis
    Zhang, Yi
    Hu, Yiming
    Guo, Fen
    JOURNAL OF BIOMATERIALS AND TISSUE ENGINEERING, 2023, 13 (01) : 18 - 23
  • [40] Simultaneous effect of miR-21 suppression and miR-143 restoration on inhibition of proliferation and migration in SW-480 colorectal cancer cells
    Tohidast, Maryam
    Amini, Mohammad
    Doustvandi, Mohammad Amin
    Hosseini, Seyed Samad
    Bilan, Farzaneh
    Mozammel, Nazila
    Sameti, Pouryia
    Mokhtarzadeh, Amir Ali
    Baradaran, Behzad
    BIOIMPACTS, 2024,